TP53 and neoplasm: Similarly, Park and colleagues (2019) described genes from canonical pathways that are prognosis-related and differ according to SHH-MB subtypes (e.g P53 and cell cycle pathways), suggesting that these signatures potentially has an association with tumor aggressiveness and therapy response21.